The maker of Ozempic and Wegovy has minimize its gross sales and revenue forecasts because it continues to fall behind within the aggressive marketplace for weight problems and diabetes therapies.
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
